Starpharmas DEP eliminates cabazitaxel neutropenia
Filed with ASX · · 4 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel active against Zika virus
- DEP cabazitaxel shows complete, sustained tumour regression
- Starpharma signs drug delivery license with AstraZeneca
- Successful completion of VivaGel study sexually active women
- Starpharma`s Bacterial Vaginosis Study gets FDA Clearance
Later from Starpharma
- Appendix 4C - Quarterly Cashflow Reoprt
- Starpharma signs license for a VivaGel condom in China
- New DEP drug delivery program initiated with AstraZeneca
- VivaGel condom receives regulatory approval in Canada
- Enrolment complete for Phase 3 VivaGel BV-R program
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma